Featured Programs
Minimizing Toxicity While Maintaining Efficacy in RCC
Moderated by Robert A. Figlin, MD, this panel discussion includes expert perspectives from Daniel J. George, MD, Sumanta Kumar Pal, MD, Brian I. Rini, MD, and Nizar M. Tannir, MD.
View Now
Avastin (bevacizumab) Plus IFN in mRCC
Ronald Bukowski, MD, and Thomas Hutson, DO, PharmD, disucss bevacizumab in metastatic renal cell carcinoma.
View Now
Most Popular Right Now